(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 February 2010 (11.02.2010)

PCT

(10) International Publication Number
WO 2010/017198 A3

(51) International Patent Classification:
C12N 15/12 (2006.01) *C07K 14/71* (2006.01)
C12N 15/62 (2006.01) *A61K 38/17* (2006.01)

(21) International Application Number:
PCT/US2009/052704

(22) International Filing Date:
4 August 2009 (04.08.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/086,121 4 August 2008 (04.08.2008) US

(71) Applicant *(for all designated States except US)*: **FIVE PRIME THERAPEUTICS, INC.** [US/US]; 1650 Owens Street, Suite 200, San Francisco, CA 94158-2261 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **MARSHALL, Shannon** [US/US]; 777 S. Eden Street #629, Baltimore, MD 21231 (US). **CHARYCH, Deborah, H.** [US/US]; 909 Taylor Street, Albany, CA 94706 (US). **SADRA, Ali** [IR/US]; 3141 Casa De Campo St. E-208, San Mateo, CA 94403 (US).

(74) Agent: **GARRETT, Arthur, S.**; Finnegan, Henderson, Farabow, Garrett &, Dunner, L.L.P., 901 New York Avenue, NW, Washington, DC 20001-4413 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
29 April 2010

WO 2010/017198 A3

(54) Title: FGFR EXTRACELLULAR DOMAIN ACIDIC REGION MUTEINS

(57) Abstract: Fibroblast growth factor receptor (FGFR) extracellular domain (ECD) acidic region muteins that have been engineered to exhibit decreased tissue binding by increasing the number of acidic amino acid residues within the D1-D2 linker region are provided. Polynucleotides encoding FGFR ECD acidic region muteins are also provided. Methods of making FGFR ECD acidic region muteins, and methods of using such molecules to treat proliferative disorders, including cancers, disorders of angiogenesis, and macular degeneration, are also provided.